Phase 1 Trial of ADI-PEG 20 plus Cisplatin in Patients with Metastatic Melanoma or other Advanced Solid Malignancies

Trial Profile

Phase 1 Trial of ADI-PEG 20 plus Cisplatin in Patients with Metastatic Melanoma or other Advanced Solid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Pegargiminase (Primary) ; Cisplatin
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 24 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 01 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Feb 2017, as reported by ClinicalTrials.gov.
    • 01 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top